Upgrade of 2024 guidance and mid-term outlook to double 2023 revenues by 2028. We are happy to share our financial results for H1 2024 and our new mid-term outlook, released earlier today. With solid progress and improved profitability and cash flow, we increased our guidance for 2024. As we strive to be the most innovative peptides CDMO, we now target to double 2023 revenue by 2028, with the EBITDA margin approaching 25%. 👉 https://lnkd.in/dWcKi6zY #halfyearresults #CDMO #peptides
Impressive growth!
Imponerande!
--
2moBest of luck!